184 related articles for article (PubMed ID: 38515954)
21. [PANCREATIC NEUROENDOCRINE TUMORS (PNET): THE DILEMMA OF SURGERY VS. WATCHFUL WAITING APPROACH].
Shafir M; Harel R; Sandler V; Haddad R; Khoury W; Bitterman A
Harefuah; 2022 Nov; 161(11):687-694. PubMed ID: 36578240
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of solid-pseudopapillary tumors of the pancreas from pancreatic neuroendocrine tumors by using endoscopic ultrasound.
Liu Y; Shi S; Hua J; Xu J; Zhang B; Liu J; Yang XJ; Yu XJ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):947-953. PubMed ID: 32144073
[TBL] [Abstract][Full Text] [Related]
24. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group.
Klein Haneveld MJ; van Treijen MJC; Pieterman CRC; Dekkers OM; van de Ven A; de Herder WW; Zandee WT; Drent ML; Bisschop PH; Havekes B; Vriens MR; Verrijn Stuart AA; Valk GD; van Leeuwaarde RS
J Clin Endocrinol Metab; 2021 Nov; 106(12):3515-3525. PubMed ID: 34333645
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States.
Jonasch E; Song Y; Freimark J; Berman R; Nguyen H; Signorovitch J; Sundaram M
Orphanet J Rare Dis; 2024 Feb; 19(1):73. PubMed ID: 38365728
[TBL] [Abstract][Full Text] [Related]
26. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Smith D; Lepage C; Vicaut E; Dominguez S; Coriat R; Dubreuil O; Lecomte T; Baudin E; Venat Bouvet L; Samalin E; Santos A; Borie O; Bisot-Locard S; Goichot B; Lombard-Bohas C
Adv Ther; 2022 Jun; 39(6):2731-2748. PubMed ID: 35419649
[TBL] [Abstract][Full Text] [Related]
27. [Expression and significance of INSM1 and SOX11 in pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm].
Cao Z; Cen HB; Zhao JH; Mei J; Qin LZ; Liao W; Ao QL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 55(4):575-581. PubMed ID: 37534634
[TBL] [Abstract][Full Text] [Related]
28. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
[TBL] [Abstract][Full Text] [Related]
29. Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Haugvik SP; Hedenström P; Korsæth E; Valente R; Hayes A; Siuka D; Maisonneuve P; Gladhaug IP; Lindkvist B; Capurso G
Neuroendocrinology; 2015; 101(2):133-42. PubMed ID: 25613442
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers for prognosis in pancreatic neuroendocrine tumors.
Zhu M; Sorenson KR; Liu R; Gould Rothberg BE; Halfdanarson TR
Endocr Relat Cancer; 2021 Oct; 28(12):773-782. PubMed ID: 34582360
[TBL] [Abstract][Full Text] [Related]
31. Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.
Phan AT
Cancer Treat Rev; 2013 Feb; 39(1):3-9. PubMed ID: 22459199
[TBL] [Abstract][Full Text] [Related]
32. Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives.
Hernandez-Rienda L; Del Olmo-García MI; Merino-Torres JF
Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422243
[TBL] [Abstract][Full Text] [Related]
33. STK33 Promotes the Growth and Progression of Human Pancreatic Neuroendocrine Tumour via Activation of the PI3K/AKT/mTOR Pathway.
Zhou B; Xiang J; Zhan C; Liu J; Yan S
Neuroendocrinology; 2020; 110(3-4):307-320. PubMed ID: 31261148
[TBL] [Abstract][Full Text] [Related]
34. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
[TBL] [Abstract][Full Text] [Related]
35. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
36. mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases.
Zhou CF; Ji J; Yuan F; Shi M; Zhang J; Liu BY; Zhu ZG
Hepatogastroenterology; 2011; 58(112):2140-3. PubMed ID: 22024086
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy.
Loosen SH; Kostev K; Eschrich J; Krieg S; Krieg A; Luedde T; Jann H; Roderburg C
Medicine (Baltimore); 2022 Dec; 101(50):e32044. PubMed ID: 36550801
[TBL] [Abstract][Full Text] [Related]
38. Impact of tumor size and location on endoscopic ultrasound-guided sampling of pancreatic neuroendocrine tumors: A recursive partitioning analysis.
Sirtl S; Mahajan UM; Auernhammer CJ; Dziadkiewicz P; Hohmann E; Wójcik M; Kos-Kudła B; Hartleb M; Knösel T; Schirra J; Mayerle J; Schulz C; Żorniak M
Pancreatology; 2022 Jun; 22(5):644-650. PubMed ID: 35589512
[TBL] [Abstract][Full Text] [Related]
39. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20-year single-center retrospective analysis.
You T; Tang H; Xu X; Ying H; Sun Z; Cheng Y; Bai C
J Neuroendocrinol; 2022 Dec; 34(12):e13211. PubMed ID: 36373196
[TBL] [Abstract][Full Text] [Related]
40. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
